Account wins from the 06/13/06 News Brief

Share this article:
Noonan Russo has reported the addition of two California biopharmaceutical companies -- Ambrx and Aerovance -- to its client roster.The agency will develop and implement integrated communications programs to raise the companies’ profiles among prospective investors, business partners and employees.  Program activities will consist of message development, key opinion leader outreach, investor identification and targeting, and media relations.Ambrx is a San Diego-based biopharmaceutical company focused on optimizing existing protein drugs. Aerovance is a Berkeley, Calif.-based company that is focused on the development and commercialization of biologics for respiratory and inflammatory diseases. Interlink Healthcare Communications has undertaken a new assignment for Enzon Pharmaceuticals, as agency of record for Oncaspar, which treats acute lymphoblastic leukemia (also called acute lymphocytic leukemia or ALL), the most common form of cancer in children. The agency will handle promotional communications, primarily directed toward sales force-driven promotion; creative execution for journal ads, direct-to-physician communications, and possibly patient and advocacy communications.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies